サマリー

健康な人の体にワクチンを接種することで、病気がなくても抗体を作り、特異的な免疫力を得ることができる。例えば、BCG接種、天然痘ワクチン接種など。
市場の分析と洞察ヒト用予防ワクチンの世界市場
COVID-19の大流行により、世界の予防用ヒトワクチン市場規模は2022年に百万米ドルと推定され、レビュー期間中にCAGR %で2028年までに百万米ドルの再調整サイズになると予測されています。この健康危機による経済変化を十分に考慮し、2021年に予防用ヒトワクチンの世界市場の％を占めた不活性化ワクチンは、2028年には百万米ドルの価値を持ち、COVID-19後の期間に修正された％のCAGRで成長すると予測されます。一方、病院セグメントは、この予測期間を通して％CAGRに変更されています。
中国の予防用ヒトワクチンの市場規模は2021年に百万米ドル、米国と欧州の予防用ヒトワクチンはそれぞれ百万米ドル、百万米ドルと評価されています。2021年の米国の割合は％、中国と欧州はそれぞれ％、％で、中国の割合は2028年には％に達すると予測され、分析期間を通じてCAGRは％である。日本、韓国、東南アジアはアジアの注目すべき市場であり、今後6年間のCAGRはそれぞれ％、％、％となっています。ヨーロッパのヒト用予防ワクチンの展望としては、ドイツが2028年までに100万米ドルに達すると予測され、予測期間中のCAGRは%となっています。
予防用ヒトワクチンの世界的な主要メーカーには、GSK、Biovac、McKesson Medical、Merck、Merial、Zoetis、Sanofiなどが挙げられます。2021年、世界の上位5社は売上高で約 %のシェアを持っています。
世界の予防用ヒトワクチンの範囲とセグメント
ヒト用予防ワクチン市場は、タイプ別と用途別に分類されます。世界の予防用ヒトワクチン市場におけるプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができるようになることでしょう。セグメント別分析では、2017年から2028年までのタイプ別およびアプリケーション別の売上、収益、予測に焦点を当てています。
タイプ別セグメント
不活性化ワクチン
弱毒性ワクチン
その他
用途別セグメント
病院
科学研究
その他
会社別
GSK
バイオバック
マッケソンメディカル
メルク
メリアル
ゾエティス
サノフィ
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
アジア太平洋地域
中国
日本
韓国
インド
オーストラリア
台湾
インドネシア
タイ
マレーシア
フィリピン
ベトナム
中南米
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
U.A.E.

ページTOPに戻る

目次

1 Study Coverage
1.1 Prophylactic Human Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Prophylactic Human Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Inactivated Vaccine
1.2.3 Attenuated Vaccine
1.2.4 Others
1.3 Market by Application
1.3.1 Global Prophylactic Human Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Scientific Research
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Prophylactic Human Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Prophylactic Human Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Prophylactic Human Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Prophylactic Human Vaccine Sales by Region
2.4.1 Global Prophylactic Human Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Prophylactic Human Vaccine by Region (2023-2028)
2.5 Global Prophylactic Human Vaccine Revenue by Region
2.5.1 Global Prophylactic Human Vaccine Revenue by Region (2017-2022)
2.5.2 Global Prophylactic Human Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Prophylactic Human Vaccine Sales by Manufacturers
3.1.1 Global Top Prophylactic Human Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Prophylactic Human Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Prophylactic Human Vaccine in 2021
3.2 Global Prophylactic Human Vaccine Revenue by Manufacturers
3.2.1 Global Prophylactic Human Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Prophylactic Human Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Prophylactic Human Vaccine Revenue in 2021
3.3 Global Prophylactic Human Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Prophylactic Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Prophylactic Human Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Prophylactic Human Vaccine Sales by Type
4.1.1 Global Prophylactic Human Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Prophylactic Human Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Prophylactic Human Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Prophylactic Human Vaccine Revenue by Type
4.2.1 Global Prophylactic Human Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Prophylactic Human Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Prophylactic Human Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Prophylactic Human Vaccine Price by Type
4.3.1 Global Prophylactic Human Vaccine Price by Type (2017-2022)
4.3.2 Global Prophylactic Human Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Prophylactic Human Vaccine Sales by Application
5.1.1 Global Prophylactic Human Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Prophylactic Human Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Prophylactic Human Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Prophylactic Human Vaccine Revenue by Application
5.2.1 Global Prophylactic Human Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Prophylactic Human Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Prophylactic Human Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Prophylactic Human Vaccine Price by Application
5.3.1 Global Prophylactic Human Vaccine Price by Application (2017-2022)
5.3.2 Global Prophylactic Human Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Prophylactic Human Vaccine Market Size by Type
6.1.1 North America Prophylactic Human Vaccine Sales by Type (2017-2028)
6.1.2 North America Prophylactic Human Vaccine Revenue by Type (2017-2028)
6.2 North America Prophylactic Human Vaccine Market Size by Application
6.2.1 North America Prophylactic Human Vaccine Sales by Application (2017-2028)
6.2.2 North America Prophylactic Human Vaccine Revenue by Application (2017-2028)
6.3 North America Prophylactic Human Vaccine Market Size by Country
6.3.1 North America Prophylactic Human Vaccine Sales by Country (2017-2028)
6.3.2 North America Prophylactic Human Vaccine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Prophylactic Human Vaccine Market Size by Type
7.1.1 Europe Prophylactic Human Vaccine Sales by Type (2017-2028)
7.1.2 Europe Prophylactic Human Vaccine Revenue by Type (2017-2028)
7.2 Europe Prophylactic Human Vaccine Market Size by Application
7.2.1 Europe Prophylactic Human Vaccine Sales by Application (2017-2028)
7.2.2 Europe Prophylactic Human Vaccine Revenue by Application (2017-2028)
7.3 Europe Prophylactic Human Vaccine Market Size by Country
7.3.1 Europe Prophylactic Human Vaccine Sales by Country (2017-2028)
7.3.2 Europe Prophylactic Human Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Prophylactic Human Vaccine Market Size by Type
8.1.1 Asia Pacific Prophylactic Human Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Prophylactic Human Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Prophylactic Human Vaccine Market Size by Application
8.2.1 Asia Pacific Prophylactic Human Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Prophylactic Human Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Prophylactic Human Vaccine Market Size by Region
8.3.1 Asia Pacific Prophylactic Human Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Prophylactic Human Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Prophylactic Human Vaccine Market Size by Type
9.1.1 Latin America Prophylactic Human Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Prophylactic Human Vaccine Revenue by Type (2017-2028)
9.2 Latin America Prophylactic Human Vaccine Market Size by Application
9.2.1 Latin America Prophylactic Human Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Prophylactic Human Vaccine Revenue by Application (2017-2028)
9.3 Latin America Prophylactic Human Vaccine Market Size by Country
9.3.1 Latin America Prophylactic Human Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Prophylactic Human Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Prophylactic Human Vaccine Market Size by Type
10.1.1 Middle East and Africa Prophylactic Human Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Prophylactic Human Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Prophylactic Human Vaccine Market Size by Application
10.2.1 Middle East and Africa Prophylactic Human Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Prophylactic Human Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Prophylactic Human Vaccine Market Size by Country
10.3.1 Middle East and Africa Prophylactic Human Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Prophylactic Human Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Overview
11.1.3 GSK Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GSK Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GSK Recent Developments
11.2 Biovac
11.2.1 Biovac Corporation Information
11.2.2 Biovac Overview
11.2.3 Biovac Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Biovac Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Biovac Recent Developments
11.3 McKesson Medical
11.3.1 McKesson Medical Corporation Information
11.3.2 McKesson Medical Overview
11.3.3 McKesson Medical Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 McKesson Medical Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 McKesson Medical Recent Developments
11.4 Merck
11.4.1 Merck Corporation Information
11.4.2 Merck Overview
11.4.3 Merck Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Merck Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Merck Recent Developments
11.5 Merial
11.5.1 Merial Corporation Information
11.5.2 Merial Overview
11.5.3 Merial Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Merial Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Merial Recent Developments
11.6 Zoetis
11.6.1 Zoetis Corporation Information
11.6.2 Zoetis Overview
11.6.3 Zoetis Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Zoetis Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Zoetis Recent Developments
11.7 Sanofi
11.7.1 Sanofi Corporation Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Prophylactic Human Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sanofi Prophylactic Human Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Prophylactic Human Vaccine Industry Chain Analysis
12.2 Prophylactic Human Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Prophylactic Human Vaccine Production Mode & Process
12.4 Prophylactic Human Vaccine Sales and Marketing
12.4.1 Prophylactic Human Vaccine Sales Channels
12.4.2 Prophylactic Human Vaccine Distributors
12.5 Prophylactic Human Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Prophylactic Human Vaccine Industry Trends
13.2 Prophylactic Human Vaccine Market Drivers
13.3 Prophylactic Human Vaccine Market Challenges
13.4 Prophylactic Human Vaccine Market Restraints
14 Key Findings in The Global Prophylactic Human Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer